CT Myocardial Perfusion Tool Helps Generate Faster, Safer Cardiac Diagnoses

A computed tomography (CT) system’s application allows clinicians to visualize myocardial ischemia.

To optimize cardiac diagnoses with simplified dose reduction technology, Toshiba Medical Systems (Tokyo, Japan) reported the US Food and Drug Administration (FDA) clearance of its CT myocardial perfusion capability. Available on Toshiba’s Aquilion One and Aquilion One ViSION Edition CT systems, the myocardial perfusion features allows clinicians to visualize myocardial ischemia with CT, providing a clinical and subsystem to streamline workflow.

The myocardial perfusion tool on Toshiba’s 320-detector-row CT scanner visualizes blood flow and anatomy within the coronary arteries to help determine the viability of the heart muscle. This enables clinicians to provide more rapid and more effective decisions on whether to undergo revascularization of coronary blockages. Toshiba’s CT Myocardial Perfusion puts patient experience first with shorter exam times and substantially lower radiation exposure, when compared with standard coronary artery disease (CAD) evaluation techniques.

“Heart disease has remained the number one cause of death in the United States, according to the Centers for Disease Control and Prevention [Atlanta, GA, USA], and new CT technology is helping diagnose cardiac disease sooner,” said Satrajit Misra, senior director, CT business unit, Toshiba. “The Aquilion One’s ability to capture the entire heart in a single rotation and its Myocardial Perfusion capability allow clinicians to make better decisions on treatment. Additionally, Toshiba’s simplified dose reduction technology, AIDR [adaptive iterative dose reduction] 3D, ensures that CT dose and safety is not a choice hospitals or patients should have to make.”

Toshiba will present its myocardial perfusion technology at the 2014 American College of Cardiology (ACC) annual meeting in Washington DC (USA), March 29–April 2, 2014.

Related Links:
Toshiba Medical Systems